SCHEMBL9522943

SCHEMBL9522943

O=C(O)c1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 10/20 0.64
THRA P10827 8/20 0.64
PPARG P37231 6/20 0.64
RXRA P19793 3/20 0.64
ITGB3 P05106 1/20 0.64
ITGAV P06756 1/20 0.64
TPMT P51580 2/20 0.57
LMNA P02545 5/20 0.56
HSD17B10 Q99714 4/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
ADORA3 P0DMS8 3/20 0.56
PDE4D Q08499 3/20 0.56
TTR P02766 2/20 0.56
ALDH1A1 P00352 2/20 0.56
MAPT P10636 2/20 0.56
CYP1A2 P05177 2/20 0.56
HTR1A P08908 2/20 0.56
CYP2C9 P11712 2/20 0.56
HTR2B P41595 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11223984 0.85 TPMT (0.49) THRBTHRAPPARGRXRAITGB3
SCHEMBL1613916 0.82 TPMT (0.68) THRBTPMTLMNAHSD17B10MEN1
SCHEMBL12764452 0.82 THRB (0.64) THRBTHRAPPARGRXRAITGB3
SCHEMBL9748136 0.81 THRB (0.67) THRBTHRAPPARGRXRATPMT
SCHEMBL4008454 0.81 PCNA (0.61) THRBTHRAPPARGRXRATPMT
SCHEMBL16167912 0.80 THRB (0.47) THRBTHRAPPARGRXRAITGB3
SCHEMBL6135835 0.79 TPMT (0.58) RXRATPMTMEN1KMT2ATTR
SCHEMBL6858181 0.79 THRB (0.46) THRBTHRAPPARGRXRAITGB3
SCHEMBL24407708 0.79 PARP15 (0.55) THRBTHRAPPARGRXRAITGB3
SCHEMBL6720943 0.79 TPMT (0.50) THRBTHRAPPARGRXRAITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114805480-A Preparation method of octreotide 江苏金斯瑞生物科技有限公司 2022-07-29 CN claimed
WO-2026107381-A1 DNA POLYMERASE THETA INHIBITORS, COMPOSITIONS THEREOF, COMPOSITIONS FURTHER COMPRISING A DNA DEPENDENT PROTEIN KINASE, AND USES OF BOTH IN GENE EDITING FIELD JUNO THERAPEUTICS, INC. (US) 2026-05-21 WO disclosed
US-20260115330-A1 RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-04-30 US disclosed
EP-4724443-A1 PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE Acrivon Therapeutics, Inc. (US) 2026-04-15 EP disclosed
US-20260097125-A1 ULTRA-LONG-ACTING PLATFORM COMPRISING FC-ADVANCED FATTY ACID CHAIN WATERSTONE PHARMACEUTICALS WUHAN CO LTD (CN) 2026-04-09 US disclosed
US-12576158-B2 Antibody drug conjugates with cleavable linkers HEIDELBERG PHARMA RESEARCH GMBH (DE) 2026-03-17 US disclosed
US-20260049178-A1 CROSSLINKING AGENTS AND MEDICAL HYDROGELS FORMED THEREFROM BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-02-19 US disclosed
US-20260041799-A1 HYDROLYSIS-RESISTANT HYDROGELS AND METHODS OF TREATMENT USING SAME BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-02-12 US disclosed
US-20260014282-A1 METHODS OF FORMING RADIOPAQUE PEPTIDES FOR USE IN MEDICAL HYDROGELS BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-01-15 US disclosed
EP-4665719-A1 SMALL MOLECULE TREATMENT OF FATTY LIVER DISEASE AND HCC ScandiEdge Therapeutics AB (SE) 2025-12-24 EP disclosed
US-20220152183-A1 CARBOCYCLIC DERIVATIVES AND CONJUGATED DERIVATIVES THEREOF, AND THEIR USE IN VACCINES GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-05-19 US disclosed
CN-112094324-B Synthesis method of carbetocin 宁波三生生物科技股份有限公司 2022-05-03 CN disclosed
EP-3972648-A1 ANTIBODY DRUG CONJUGATES WITH CLEAVABLE LINKERS Heidelberg Pharma Research GmbH (DE) 2022-03-30 EP disclosed
CN-114144201-A Antibody drug conjugates containing a cleavable linker 海德堡医药研究有限责任公司 2022-03-04 CN disclosed
WO-2022043238-A1 PENTAVALENT VACCINE AGAINST NEISSERIA MENINGITIDIS COMPRISING A SYNTHETIC MEN A ANTIGEN GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-03-03 WO disclosed
CN-114126620-A FGFR inhibitors and methods of use thereof 传达治疗有限公司 2022-03-01 CN disclosed
US-5273885-A Using a polyiodothyronine analog of a phenyl compound containing a hydroxyl group ortho to an iodine SYNTEX (U.S.A.) INC. (US) 1993-12-28 US disclosed
EP-0204523-B1 GLUCOSE-6-PHOSPHATE DEHYDROGENASE CONJUGATES, THEIR PREPARATION AND USE SYNTEX (U.S.A.) INC. (US) 1992-02-26 EP disclosed
US-4847195-A IMMUNOASSAY SYNTEX (U.S.A.) INC. (US) 1989-07-11 US disclosed
EP-0204523-A2 Glucose-6-phosphate dehydrogenase conjugates, their preparation and use SYNTEX (U.S.A.) INC. (US) 1986-12-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097125-A1 ULTRA-LONG-ACTING PLATFORM COMPRISING FC-ADVANCED FATTY ACID CHAIN FCGR2A, FCGR1A, FCGR3B THRB 2502/4885THRA 922/4885PPARG 59/4885
US-20260115330-A1 RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS KLK3, BRDT, BPHL THRB 955/4885THRA 358/4885PPARG 734/4885
US-20260049178-A1 CROSSLINKING AGENTS AND MEDICAL HYDROGELS FORMED THEREFROM NPPA, MACF1, IGF1R THRB 651/4885THRA 39/4885PPARG 2055/4885
US-20260014282-A1 METHODS OF FORMING RADIOPAQUE PEPTIDES FOR USE IN MEDICAL HYDROGELS IAPP, NPPA, ARG1 THRB 434/4885THRA 330/4885PPARG 1195/4885
US-12576158-B2 Antibody drug conjugates with cleavable linkers PTMS, C3AR1, ANPEP THRB 1161/4885THRA 1557/4885PPARG 4867/4885
US-20260041799-A1 HYDROLYSIS-RESISTANT HYDROGELS AND METHODS OF TREATMENT USING SAME PAM, CRYAA, COL1A1 THRB 2135/4885THRA 562/4885PPARG 4275/4885
US-20220152183-A1 CARBOCYCLIC DERIVATIVES AND CONJUGATED DERIVATIVES THEREOF, AND THEIR USE IN VACCINES AADAC, NOD2, HDAC3 THRB 4254/4885THRA 4294/4885PPARG 1719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.